Advertisement

Modulation of salivary ICAM-1 and SIRT1 by disease modifying drugs in undepressed relapsing-remitting multiple sclerosis patients

Published:October 20, 2022DOI:https://doi.org/10.1016/j.msard.2022.104257

      Highlights

      • Adhesion molecules such as Intercellular adhesion molecule-1 (ICAM-1) and surtins such as SIRT1 are gaining attention as important players in multiple sclerosis.
      • We studied, for the first time, the salivary expression of ICAM-1 and SIRT1 in MS patients receiving either interferon-β or fingolimod compared to controls.
      • The interferon-β treated patients showed about 10- fold higher ICAM expression compared to the control, while the fingolimod treated group showed a non -significant increase of ICAM levels compared to the control.
      • ICAM-1 and SIRT1 salivary expression might be affected with fingolimod or INF- β treatment which should be investigated more in the future.

      Abstract

      Background

      The pathophysiology of Multiple Sclerosis (MS) is multifactorial where the correlation between inflammation and MS is evident. Adhesion molecules such as Intercellular adhesion molecule-1 (ICAM-1) are implicated in MS. SIRT1 is a member of surtins family that play a protective role in neurodegenerative and inflammatory diseases. Although previously studied in Relapsing-Remitting Multiple Sclerosis (RRMS) patients, however the salivary expression of ICAM-1 and SIRT1 have not been yet studied in patients receiving fingolimod or interferon-β. Therefore, the present research aimed to investigate the expression of salivary ICAM-1 and SIRT1 in RRMS patients treated with fingolimod or interferon-β compared to controls.

      Methods

      RRMS patients attending the neurology department of AL-Bashir Hospital were recruited. Patients’ demographics, clinical information, and psychiatric status were evaluated (depression, anxiety and stress). Afterward, matched controls were recruited, then unstimulated whole saliva was obtained from the participants. The salivary expression of ICAM-1 and SIRT1 was investigated using western blot and normalized with β-actin.

      Results

      Data were analyzed from 53 participants: 26 on fingolimod, 14 on interferon-β, and 13 control. The interferon-β treated patients showed a significantly (p < 0.001) higher ICAM-1 expression and lower SIRT1 expression (p < 0.05) compared to the control. Levels of ICAM-1 and SIRT1 did not vary between fingolimod and control.

      Conclusion

      ICAM-1 and SIRT1 expression might be affected with fingolimod or INF- β treatment which should be investigated more in the future.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Abdolvahab M.H.
        • Mofrad M.R.K.
        • Schellekens H.
        Interferon beta: from molecular level to therapeutic effects.
        Int. Rev. Cell Mol. Biol. 2016; 326: 343-372
        • Aldughmi M.
        • Al-Shorman A.
        • Khalil H.
        • El-Salem K.
        • Alghwiri A.
        Translation and validation of the Arabic version of the patient determined disease steps in people with multiple sclerosis.
        Physiother. Theory Pract. 2022; 38: 1281-1288https://doi.org/10.1080/09593985.2020.1839988
      1. Aljishi, R.H., Almatrafi, R.J., Alzayer, Z.A., Alkhamis, B.A., Yaseen, E.E., Alkhotani, A.M. Prevalence of Anxiety and Depression in Patients With Multiple Sclerosis in Saudi Arabia: A Cross-Sectional Study. Cureus. 2021 29;13(12).

        • Almeida M.
        • Porter R.M.
        Sirtuins and FoxOs in osteoporosis and osteoarthritis.
        Bone. 2019; 121: 284-292https://doi.org/10.1016/J.BONE.2019.01.018
        • Ammar R.A.
        • Mohamed A.F.
        • Kamal M.M.
        • Safar M.M.
        • Abdelkader N.F.
        Neuroprotective effect of liraglutide in an experimental mouse model of multiple sclerosis: role of AMPK/SIRT1 signaling and NLRP3 inflammasome.
        Inflammopharmacology. 2022; 30: 919-934https://doi.org/10.1007/S10787-022-00956-6
        • Arnold D.L.
        • Banwell B.
        • Bar-Or A.
        • Ghezzi A.
        • Greenberg B.M.
        • Waubant E.
        • Giovannoni G.
        • Wolinsky J.S.
        • Gärtner J.
        • Rostásy K.
        • Krupp L.
        • Tardieu M.
        • Brück W.
        • Stites T.E.
        • Pearce G.L.
        • Häring D.A.
        • Merschhemke M.
        • Chitnis T.
        Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIG MS study.
        J. Neurol. Neurosurg. Psychiatry. 2020; 91: 483-492https://doi.org/10.1136/JNNP-2019-322138
        • Cohen J.A.
        • Barkhof F.
        • Comi G.
        • Hartung H.P.
        • Khatri B.O.
        • Montalban X.
        • Pelletier J.
        • Capra R.
        • Gallo P.
        • Izquierdo G.
        • Tiel-Wilck K.
        • de Vera A.
        • Jin J.
        • Stites T.
        • Wu S.
        • Aradhye S.
        • Kappos L.
        Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
        N. Engl. J. Med. 2010; 362: 402-415https://doi.org/10.1056/NEJMOA0907839
        • Cohen J.A.
        • Khatri B.
        • Barkhof F.
        • Comi G.
        • Hartung H.P.
        • Montalban X.
        • Pelletier J.
        • Stites T.
        • Ritter S.
        • Von Rosenstiel P.
        • Tomic D.
        • Kappos L.
        Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.
        J. Neurol. Neurosurg. Psychiatry. 2016; 87: 468-475https://doi.org/10.1136/JNNP-2015-310597
        • Cohen S.
        • Kamarck T.
        • Mermelstein R.
        Perceived stress scale.
        Measuring Stress: a Guide for Health and Social Scientists. 10. Sheldon Cohen, 1994: 1-2
        • Comi G.
        • Patti F.
        • Rocca M.A.
        • Mattioli F.C.
        • Amato M.P.
        • Gallo P.
        • Centonze D.
        • Pozzilli C.
        • Saccà F.
        • Bergh F.T.
        • Bartezaghi M.
        • Turrini R.
        • Filippi M.
        • Chisari C.G.
        • Marfia G.A.
        • Morra V.B.
        • Capra R.
        • Bianchi V.
        • Ghezzi A.
        • Roscio M.
        • Sangalli F.
        • Pietrolongo E.
        • Francia A.
        • Danni M.C.
        • Nocentini U.
        • Bramanti P.
        • Tedeschi G.
        • Maimone D.
        • Grimaldi L.M.E.
        • Scarpini E.A.
        • Uccelli A.
        • Rottoli M.
        • Ruggieri S.
        • Trojano M.
        • Bergamaschi R.
        • Buttmann M.
        • Rieckmann P.
        • Safavi A.
        Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
        J. Neurol. 2017; 264: 2436-2449https://doi.org/10.1007/S00415-017-8642-5
        • Cournu-Rebeix I.
        • Génin E.
        • Lesca G.
        • Azoulay-Cayla A.
        • Tubridy N.
        • Noé E.
        • Clanet M.
        • Edan G.
        • Clerget-Darpoux F.
        • Sémana G.
        • Fontaine B.
        Intercellular adhesion molecule-1: a protective haplotype against multiple sclerosis.
        Genes Immun. 2003; 4: 518-523https://doi.org/10.1038/SJ.GENE.6364009
        • D'haeseleer M.
        • Cambron M.
        • Vanopdenbosch L.
        • De Keyser J.
        Vascular aspects of multiple sclerosis.
        Lancet Neurol. 2011; 10: 657-666
        • Dang R.
        • Wang M.
        • Li X.
        • Wang H.
        • Liu L.
        • Wu Q.
        • Zhao J.
        • Ji P.
        • Zhong L.
        • Licinio J.
        Edaravone ameliorates depressive and anxiety-like behaviors via Sirt1/Nrf2/HO-1/Gpx4 pathway.
        J. Neuroinflamm. 2022; 19: 1-29
        • Dessein P.H.
        • Joffe B.I.
        • Singh S.
        Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis.
        Arthritis Res. Ther. 2005; 7: 1
        • Droogan A.G.
        • McMillan S.A.
        • Douglas J.P.
        • Hawkins S.A.
        Serum and cerebrospinal fluid levels of soluble adhesion molecules in multiple sclerosis: predominant intrathecal release of vascular cell adhesion molecule-1.
        J. Neuroimmunol. 1996; 64: 185-191https://doi.org/10.1016/0165-5728(95)00174-3
        • Elovaara I.
        • Ukkonen M.
        • Leppäkynnäs M.
        • Lehtimäki T.
        • Luomala M.
        • Peltola J.
        • Dastidar P.
        Adhesion molecules in multiple sclerosis.
        Arch. Neurol. 2000; 57: 546https://doi.org/10.1001/archneur.57.4.546
        • Fawcett J.
        • Holness C.L.L.
        • Needham L.A.
        • Turley H.
        • Gattert K.C.
        • Mason D.Y.
        • Simmons D.L.
        Molecular cloning of ICAM-3, a third ligand for LFA-1, constitutively expressed on resting leukocytes.
        Nature. 1992; 360: 481-484https://doi.org/10.1038/360481a0
        • Frischer J.M.
        • Bramow S.
        • Dal-Bianco A.
        • Lucchinetti C.F.
        • Rauschka H.
        • Schmidbauer M.
        • Laursen H.
        • Sorensen P.S.
        • Lassmann H.
        The relation between inflammation and neurodegeneration in multiple sclerosis brains.
        Brain. 2009; 132: 1175-1189
        • Gammoh O.S.
        • Al-Smadi A.
        • Al-Awaida W.
        • Badr M.M.
        • Qinna N.A.
        Increased salivary nitric oxide and G6PD activity in refugees with anxiety and stress.
        Stress Heal. 2016; 32: 435-440https://doi.org/10.1002/smi.2666
        • Jahromi N.H.
        • Marchetti L.
        • Moalli F.
        • Duc D.
        • Basso C.
        • Tardent H.
        • Kaba E.
        • Deutsch U.
        • Pot C.
        • Sallusto F.
        • Stein J.V.
        • Engelhardt B.
        Intercellular adhesion molecule-1 (ICAM-1) and ICAM-2 differentially contribute to peripheral activation and CNS entry of autoaggressive Th1 and Th17 Cells in experimental autoimmune encephalomyelitis.
        Front. Immunol. 2020; 10: 3056https://doi.org/10.3389/FIMMU.2019.03056/BIBTEX
        • Hunter S.F.
        • Agius M.
        • Miller D.M.
        • Cutter G.
        • Barbato L.
        • McCague K.
        • Meng X.
        • Agashivala N.
        • Chin P.
        • Hollander E.
        Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: an analysis from the EPOC (Evaluate Patient OutComes) trial.
        J. Neurol. Sci. 2016; 365: 190-198https://doi.org/10.1016/j.jns.2016.03.024
        • Jia Y.Y.
        • Gao P.
        • Chen H.Z.
        • Wan Y.Z.
        • Zhang R.
        • Zhang Z.Q.
        • Yang R.F.
        • Wang X.
        • Xu J.
        • Liu D.P.
        SIRT1 suppresses PMA and ionomycin-induced ICAM-1 expression in endothelial cells.
        Sci. China Life Sci. 2013; https://doi.org/10.1007/s11427-012-4407-7
      2. Karimi, S., Andayeshgar, B., Khatony, A., 2020. Prevalence of anxiety, depression, and stress in patients with multiple sclerosis in Kermanshah-Iran: a cross-sectional study. BMC psychiatry. 2020;20(1): 1–8.

        • Karimi S.
        • Andayeshgar B.
        • Khatony A.
        Prevalence of anxiety, depression, and stress in patients with multiple sclerosis in Kermanshah-Iran: a cross-sectional study.
        BMC Psychiatry. 2020; 20: 1-8
      3. Karlík, M., Valkovič P., Hančinová V., Krížová, L., Tóthová, Ľ., Celec, P. Markers of oxidative stress in plasma and saliva in patients with multiple sclerosis. Clinical biochemistry. 2015 1;48(1-2):24–8.

        • Khatri B.
        • Barkhof F.
        • Comi G.
        • Hartung H.P.
        • Kappos L.
        • Montalban X.
        • Pelletier J.
        • Stites T.
        • Wu S.
        • Holdbrook F.
        • Zhang-Auberson L.
        • Francis G.
        • Cohen J.A.
        Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
        Lancet Neurol. 2011; 10: 520-529https://doi.org/10.1016/S1474-4422(11)70099-0
        • Kroenke K.
        • Spitzer R.L.
        • Williams J.B.W.
        The PHQ-9: validity of a brief depression severity measure.
        J. Gen. Intern. Med. 2001; 16: 606-613
        • Lassmann H.
        • Rössler K.
        • Zimprich F.
        • Vass K.
        Expression of adhesion molecules and histocompatibility antigens at the blood-brain barrier.
        Brain Pathol. 1991; 1: 115-123https://doi.org/10.1111/J.1750-3639.1991.TB00648.X
        • Trojano M.
        • Avolio C.
        • Ruggieri M.
        • Defazio G.
        • Giuliani F.
        • Paolicelli D.
        • Livrea P.
        Serum soluble intercellular adhesion molecule-I in MS: relation to clinical and Gd-MRI activity and to rIFN beta-Ib treatment.
        Mult. Scler. 1998; 4: 183-187https://doi.org/10.1177/135245859800400318
        • Manconi B.
        • Liori B.
        • Cabras T.
        • Vincenzoni F.
        • Iavarone F.
        • Lorefice L.
        • Cocco E.
        • Castagnola M.
        • Messana I.
        • Olianas A.
        Top-down proteomic profiling of human saliva in multiple sclerosis patients.
        J. Proteomics. 2018; 187: 212-222
        • Martin A.
        • Tegla C.A.
        • Cudrici C.D.
        • Kruszewski A.M.
        • Azimzadeh P.
        • Boodhoo D.
        • Mekala A.P.
        • Rus V.
        • Rus H.
        Role of SIRT1 in autoimmune demyelination and neurodegeneration.
        Immunol. Res. 2015; 61: 187-197https://doi.org/10.1007/S12026-014-8557-5
        • Mirzaii-Dizgah M.H.
        • Mirzaii-Dizgah M.R.
        • Mirzaii-Dizgah I.
        Serum and saliva total tau protein as a marker for relapsing-remitting multiple sclerosis.
        Med. Hypotheses. 2020; 135109476
        • Mojaverrostami S.
        • Pasbakhsh P.
        • Madadi S.
        • Nekoonam S.
        • Zarini D.
        • Noori L.
        • Shiri E.
        • Salama M.
        • Zibara K.
        • Kashani I.R.
        Calorie restriction promotes remyelination in a cuprizone-induced demyelination mouse model of multiple sclerosis.
        Metab. Brain Dis. 2020; 35: 1211-1224https://doi.org/10.1007/S11011-020-00597-0
        • Montalban X.
        • Comi G.
        • O'connor P.
        • Gold S.M.
        • De Vera A.
        • Eckert B.
        • Kappos L.
        Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.
        Mult. Scler. J. 2011; 17: 1341-1350
        • Nimmagadda V.K.C.
        • Makar T.K.
        • Chandrasekaran K.
        • Sagi A.R.
        • Ray J.
        • Russell J.W.
        • Bever C.T.
        SIRT1 and NAD+ precursors: therapeutic targets in multiple sclerosis a review.
        J. Neuroimmunol. 2017; 304: 29-34https://doi.org/10.1016/J.JNEUROIM.2016.07.007
        • Pang J.
        • Xiong H.
        • Ou Y.
        • Yang H.
        • Xu Y.
        • Chen S.
        • Lai L.
        • Ye Y.
        • Su Z.
        • Lin H.
        • Huang Q.
        • Xu X.
        • Zheng Y.
        SIRT1 protects cochlear hair cell and delays age-related hearing loss via autophagy.
        Neurobiol. Aging. 2019; 80: 127-137https://doi.org/10.1016/J.NEUROBIOLAGING.2019.04.003
        • Pegoretti V.
        • Swanson K.A.
        • Bethea J.R.
        • Probert L.
        • Eisel U.L.M.
        • Fischer R.
        Inflammation and oxidative stress in multiple sclerosis: consequences for therapy development.
        Oxidative Med. Cell. Longev. 2020; 2020https://doi.org/10.1155/2020/7191080
        • Piotrzkowska D.
        • Miller E.
        • Kucharska E.
        • Niwald M.
        • Majsterek I.
        Association of miRNA and mRNA levels of the clinical onset of multiple sclerosis patients.
        Biology. 2021; 10 (Basel)https://doi.org/10.3390/BIOLOGY10060554
      4. Prasad, S., Tyagi, A.K., Aggarwal, B.B. Detection of inflammatory biomarkers in saliva and urine: potential in diagnosis, prevention, and treatment for chronic diseases. Experimental Biology and Medicine. 2016;241(8):783–99.

        • Prozorovski T.
        • Ingwersen J.
        • Lukas D.
        • Göttle P.
        • Koop B.
        • Graf J.
        • Schneider R.
        • Franke K.
        • Schumacher S.
        • Britsch S.
        • Hartung H.P.
        • Küry P.
        • Berndt C.
        • Aktas O.
        Regulation of sirtuin expression in autoimmune neuroinflammation: induction of SIRT1 in oligodendrocyte progenitor cells.
        Neurosci. Lett. 2019; 704: 116-125https://doi.org/10.1016/J.NEULET.2019.04.007
        • Rieckmann P.
        • Martin S.
        • Weichselbraun I.
        • Albrecht M.
        • Kitze B.
        • Weber T.
        • Tumani H.
        • Broocks A.
        • Lüer W.
        • Helwig A.
        • Poser S.
        Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse.
        Neurology. 1994; 44: 2367-2372https://doi.org/10.1212/WNL.44.12.2367
        • Sharief M.K.
        • Noori M.A.
        • Ciardi M.
        • Cirelli A.
        • Thompson E.J.
        Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF-alpha and blood-brain barrier damage.
        J. Neuroimmunol. 1993; 43: 15-21https://doi.org/10.1016/0165-5728(93)90070-F
        • Shawkatová I.
        • Javor J.
        • Párnická Z.
        • Bucová M.
        • Čopíková-Cudráková D.
        • Michalík J.
        • Gmitterová K.
        • Čierny D.
        • Buc M.
        • Ďurmanová V.
        Analysis of ICAM1 gene polymorphism in Slovak multiple sclerosis patients.
        Folia Microbiol. 2017; 62 (Praha).: 287-293https://doi.org/10.1007/S12223-017-0499-6
        • Spencer J.I.
        • Bell J.S.
        • DeLuca G.C.
        Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier.
        J. Neurol. Neurosurg. Psychiatry. 2018; 89: 42-52
      5. Spitzer, R.L., Kroenke, K., Williams, J.B., Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of internal medicine. 2006 22;166(10):1092–7.

        • Stein S.
        • Matter C.M.
        Protective roles of SIRT1 in atherosclerosis.
        Cell Cycle. 2011; 10: 640-647https://doi.org/10.4161/cc.10.4.14863
        • Stein S.
        • Schäfer N.
        • Breitenstein A.
        • Besler C.
        • Winnik S.
        • Lohmann C.
        • Heinrich K.
        • Brokopp C.E.
        • Handschin C.
        • Landmesser U.
        • Tanner F.C.
        • Lüscher T.F.
        • Matter C.M.
        SIRT1 reduces endothelial activation without affecting vascular function in ApoE-/- mice.
        Aging. 2010; 2 (Albany NY): 353https://doi.org/10.18632/AGING.100162
        • Sun H.
        • Wang J.
        • Guo L.
        • Wang Y.
        • Zhang J.
        • Wang J.
        • Quan M.
        • Li B.
        The combined treatment of NAD + and atorvastatin ameliorates the development of experimental autoimmune encephalomyelitis in C57BL/6 mice.
        J. Neuroimmunol. 2020; 350https://doi.org/10.1016/J.JNEUROIM.2020.577429
        • Szarka A.
        • Rigo J.J.
        • Lazar L.
        • Beko G.
        • Molvarec A.
        Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array.
        BMC Immunol. 2010; 11: 59https://doi.org/10.1186/1471-2172-11-59
        • Tauil C.B.
        • da Rocha Lima A.D.
        • Ferrari B.B.
        • da Silva V.A.G.
        • Moraes A.S.
        • da Silva F.M.
        • Melo-Silva C.A.
        • Farias A.S.
        • Brandao C.O.
        • dosSantos Leonilda M.B.
        Depression and anxiety in patients with multiple sclerosis treated with interferon-beta or fingolimod: role of indoleamine 2, 3-dioxygenase and pro-inflammatory cytokines.
        Brain Behav. Immu. Health. 2020; 9100162
        • Tegla C.A.
        • Azimzadeh P.
        • Andrian-Albescu M.
        • Martin A.
        • Cudrici C.D.
        • Trippe R.
        • Sugarman A.
        • Chen H.
        • Boodhoo D.
        • Vlaicu S.I.
        • Royal W.
        • Bever C.
        • Rus V.
        • Rus H.
        SIRT1 is decreased during relapses in patients with multiple sclerosis.
        Exp. Mol. Pathol. 2014; 96: 139-148https://doi.org/10.1016/J.YEXMP.2013.12.010
        • Thompson A.J.
        • Banwell B.L.
        • Barkhof F.
        • Carroll W.M.
        • Coetzee T.
        • Comi G.
        • Correale J.
        • Fazekas F.
        • Filippi M.
        • Freedman M.S.
        Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
        Lancet Neurol. 2018; 17: 162-173
        • Washington R.
        • Burton J.
        • Todd R.F.
        • Newman W.
        • Dragovic L.
        • Dore-Duffy P.
        Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis.
        Ann. Neurol. 1994; 35: 89-97https://doi.org/10.1002/ANA.410350114
        • Watroba M.
        • Szukiewicz D.
        Sirtuins promote brain homeostasis, preventing Alzheimer's disease through targeting neuroinflammation.
        Front. Physiol. 2022; 13https://doi.org/10.3389/FPHYS.2022.962769
        • Xie L.
        • Huang R.
        • Liu S.
        • Wu W.
        • Su A.
        • Li R.
        • Liu Xu
        • Lei Y.
        • Sun H.
        • Liu X.
        • Xu S.
        A positive feedback loop of SIRT1 and miR17HG promotes the repair of DNA double-stranded breaks.
        Cell Cycle. 2019; 18: 2110-2123https://doi.org/10.1080/15384101.2019.1641388/SUPPL_FILE/KCCY_A_1641388_SM3221.DOC
        • Zhang N.
        • Zhang R.
        • Loers G.
        • Liu C.
        • Jin L.
        • Petridis A.K.
        • Zheng X.
        • Wang Z.
        • Siebert H.C.
        Cuprizone-induced demyelination in mouse hippocampus is alleviated by ketogenic diet.
        J. Agric. Food Chem. 2020; 68: 11215-11228https://doi.org/10.1021/ACS.JAFC.0C04604
        • Zimmerman T.
        • Blanco F.
        Inhibitors targeting the LFA-1/ICAM-1 cell-adhesion interaction: design and mechanism of action.
        Curr. Pharm. Des. 2008; 14: 2128-2139https://doi.org/10.2174/138161208785740225
        • Zou B.
        • Miao C.
        • Chen J.
        Depression and perceived stress, but not anxiety, are associated with elevated inflammation in an obese adult population.
        Risk Manag. Healthc. Policy. 2020; 13: 1489